Olaparib
BRCA1-Related Cancer Predisposition
Explore 10 assets in BRCA1-Related Cancer Predisposition →Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04090567CT.gov Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer | — | Recruiting | — | — | — |
NCT03943173CT.gov Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery | — | Active Not Recruiting | — | — | — |
NCT02953457CT.gov Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation | — | Completed | — | — | — |
NCT00516373CT.gov A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · BRCA1-Related Cancer Predisposition
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Olaparib (this asset) | M.D. Anderson Cancer Center | P2 | BB · 69 |
| Niraparib | Qian Qin | P3 | B |
| Veliparib | Steven J Isakoff, MD, PhD | P2 | B |
| Durvalumab | Roswell Park Cancer Institute | P2 | B |
| Rucaparib | University of Washington | P2 | B |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | Roswell Park Cancer Institute | P2 | B |
| Ceralasertib | M.D. Anderson Cancer Center | P2 | CCC |
| Pembrolizumab | Rutgers, The State University of New Jersey | P2 | CCC |
| Talazoparib | Pfizer | P2 | CCC |
+8 more in the BRCA1-Related Cancer Predisposition cohort
Other indications for Olaparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 73 |
| Fallopian Tube Serous Adenocarcinoma | — | P3 | BBB · 72 |
| Ovarian Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- NiraparibQian QinB
- VeliparibSteven J Isakoff, MD, PhDB
- DurvalumabRoswell Park Cancer InstituteB
- RucaparibUniversity of WashingtonB
- Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, DimerRoswell Park Cancer InstituteB
Citation
Floatz Terminal. Olaparib in BRCA1-Related Cancer Predisposition. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/olaparib-brca1-related-cancer-predisposition
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →